TM Bibliothèque de composés

The Diversity Core Library Part 1 comprises over 50,000 compounds selected from a pool of 1.6 million compounds. This collection emphasizes the diversity of compound structures obtained after filtering out PAINS, REOS and MedChem filters.

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981._x000D_ _x000D_ Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function._x000D_ _x000D_ The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

The library offers a solution for establishing a foundation in the early stages of constructing a large screening library due to its large-scale supply and high cost-effectiveness. This foundation supports subsequent drug-like screening and cutting-edge research involving multiple targets and pathways.

<p>A unique collection of 2808 approved drugs for high throughput screening (HTS) and high content screening (HCS);</p>

<p>3158 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);</p>

A unique collection of xnum EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 343 protease and proteasome inhibitors for research in chemical genomics, and drug screening;

<p>A unique collection of xnum microtubule-targeted compounds can be used in HTS and HCS;</p>

<p>xnum well-chosen unique AMPK-targeted small molecules；</p>

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new

<p>A unique collection of 420 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with</p>

<p>A unique collection of 759 cytoskeleton-related compounds, can be used for HTS and HCS；</p>

Well-chosen xnum compounds with unique structures targeting transcription factor;

A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

<p>A unique collection of xnum GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target</p>

<p>A unique collection of 531 nuclear receptor signaling targeted compounds for high throughput and high content screening;</p>

<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>

<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>

<p>Contains xnum active small molecules for research related to post-translational modifications (PTMs);</p>